|
[1]OTT JJ, STEVENS GA, GROEGR J, et al.Global epidemiology of hepatitis B virus infection:New estimates of age-specific HBsAg seroprevalence and endemicity[J].Vaccine, 2012, 30 (12) :2212-2219.
|
|
[2]GBD 2013 Mortality and Causes of Death Collaborators.Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:A systematic analysis for the Global Burden of Disease Study 2013[J].Lancet, 2015, 385 (9963) :117-171.
|
|
[3]PATTULLO V.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression-prevention is better than cure[J].World J Hepatol, 2015, 7 (7) :954-967.
|
|
[4]CHEUNG KS, SETO WK, LAI CL et al.Prevention and management of hepatitis B virus reactivation in cancer patients[J].Hepatol Int, 2016, 10 (3) :407-414.
|
|
[5]KUSUMOTO S, TANAKA Y, MIZOKAMI M, et al.Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma[J].Int J Hematol, 2009, 90 (1) :13-23.
|
|
[6]MOSES SE, LIM Z, ZUCKERMAN MA.Hepatitis B virus infection:pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients[J].Expert Rev Anti Infect Ther, 2011, 9 (10) :891-899.
|
|
[7]HWANG JP, Lok ASF.Management of patients with hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (4) :209-219.
|
|
[8]CHOU CK, WANG LH, LIN HM, et al.Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells[J].Hepatology, 1992, 16 (1) :13-18.
|
|
[9]TAVAKOLPOUR S, ALAVIAN SM, SALI S.Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention:A comprehensive review[J].Hepat Mon, 2016, 16 (4) :e35810.
|
|
[10]KIM E, YUNE S, HA JM, et al.Hepatitis B virus reactivation during anti-cancer chemotherapy in patients with past hepatitis B virus infection[J].Hepatogastroenterology, 2014, 61 (134) :1704-1711.
|
|
[11]YEO W, ZEE B, ZHONG S, et al.Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J].Br J Cancer, 2004, 90 (7) :1306-1311.
|
|
[12]COLUCCIO C, BEGINI P, MARZANO A, et al.Hepatitis B in patients with hematological diseases:An update[J].World J Hepatol, 2017, 9 (25) :1043-1053.
|
|
[13]PERRILLO RP, GISH R, FALCK-YTTER YT.American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148 (1) :221-244.
|
|
[14]CHEUNG KS, SETO WK, LAI CL, et al.Prevention and management of hepatitis B virus reactivation in cancer patients[J].Hepatology Int, 2016, 10 (3) :407-414.
|
|
[15]SHIH CA, CHEN WC, YU HC, et al.Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis[J].PLo SOne, 2015, 18:e0132426.
|
|
[16]KIM SJ, HSU C, SONG YQ, et al.Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab:Analysis from the Asia Lymphoma Study Group[J].Eur J Cancer, 2013, 49 (16) :3486-3496.
|
|
[17]DI BA, LOK, AS, MARTIN P, et al.Recent US Food and Drug Administration warnings on hepatitis B reactivation with immunesuppressing and anticancer drugs:Just the tip of the iceberg?[J].Hepatology, 2015, 61 (2) :703-711.
|
|
[18]SHIBOLET O, ILAN Y, GILLIN S, et al.Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers[J].Blood, 2002, 100 (2) :391-396.
|
|
[19]HWANG JP, FISCH MJ, ZHANG H, et al.Low rates of hepatitis B virus screening at the onset of chemotherapy[J].J Oncol Pract, 2012, 8 (4) :32-39.
|
|
[20]WEINBAUM CM, WILLIAMS I, MAST EE, et al.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[J].Hepatology, 2009, 49 (5 Suppl) :s35-s44.
|
|
[21]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.
|
|
[22]LIAW YF, LEUNG N, KAQ JH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:A 2008 update[J].Hepatol Int, 2008, 2 (3) :263-283.
|
|
[23]LOK AS, MCMAHON BJ.Chronic hepatitis B:Update 2009[J].Hepatology, 2009, 50 (3) :661-662.
|
|
[24]ARTZ AS, SOMERFIELD MR, Feld JJ, et al.American society of clinical oncology provisional clinical opinion:Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases[J].J Clin Oncol, 2010, 28 (19) :3199-3202.
|
|
[25]HAY AE, MEYER RM.Hepatitis B, rituximab, screening, and prophylaxis:Effectiveness and cost effectiveness[J].J Clin Oncol, 2012, 30 (26) :3155-3157.
|
|
[26]Expert Committee for Antiviral Therapy for Special Patients with Chronic Hepatitis B.Expert consensus on antiviral therapy for special patients with chronic hepatitis B:An update in 2015[J].JClin Hepatol, 2015, 31 (8) :1185-1192. (in Chinese) 慢性乙型肝炎特殊患者抗病毒治疗专家委员会.慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新[J].临床肝胆病杂志, 2015, 31 (8) :1185-1192.
|
|
[27]YUEN MF.Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy[J].Hepatol Int, 2016, 10 (1) :102-105.
|
|
[28]MA J, QI SK, MIAO XH, et al.Consensus of Chinese experts on HBV reactivation prevention and treatment for lymphoma immunotherapy[J].Chin Clin Oncol, 2013, 18 (10) :935-942. (in Chinese) 马军, 秦叔逵, 缪晓辉, 等.淋巴瘤免疫化疗HBV再激活预防和治疗中国专家共识[J].临床肿瘤学杂志, 2013, 18 (10) :935-942.
|
|
[29]SETO WK.Hepatitis B virus reactivation during immunosuppressive therapy:Appropriate risk stratification[J].World J Hepatol, 2015, 7 (6) :825-830.
|
|
[30]YOO JJ, CHO EJ, CHO YY, et al.Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation[J].Liver Int, 2015, 35 (12) :2530-2536.
|
|
[31]LOOMBA R, ROWLEY A, WESLEY R, et al.Systematic review:The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J].Ann Intern Med, 2008, 148 (7) :519-528.
|
|
[32]LOK AS, LAI CL, LEUNG N, et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J].Gastroenterology, 2003, 125 (6) :1714-1722.
|
|
[33]LI P, XU H, DING HG.An except of Italian consensus guidelines for the recommendations for screening, monitoring, prevention, prophylax is and therapy of hepatitis B virus reactivation in patients with haematological malignancies and patients who underwent haematological stem cell transplantation a position paper (2017) [J].J Clin Hepatol, 2017, 33 (11) :2087-2090. (in Chinese) 李鹏, 徐辉, 丁惠国.《2017年意大利共识指南:血液系统恶性肿瘤以及接受造血干细胞移植患者HBV再激活的筛查、监测、预防和预防性治疗的建议》摘译[J].临床肝胆病杂志, 2017, 33 (11) :2087-2090.
|
|
[34]ZHANG MY, ZHU GQ, SHI KQ, et al.Systematic review with network meta-analysis:Comparative efficacy of oral nucleos (t) ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation[J].Oncotarget, 2016, 7 (21) :30642-30658.
|
|
[35]KOSKINAS JS, DEUTSCH M, ADAMIDI S, et al.The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients.A real life experience from a tertiary center[J].Eur J Intern Med, 2014, 25 (8) :768-771.
|
|
[36]PIPILI C, CHOLONGITAS E, PAPATHEODORIDIS G.Review article:Nucleos (t) ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther, 2014, 39 (1) :35-46.
|
|
[37]WANG Y, ZHANG C, LI HY, et al.The influence of entecavir on renal function during long-term nucleotide therapy in patients with chronic hepatitis B[J].J Clin Exp Med, 2017, 16 (15) :1502-1505. (in Chinese) 王宇, 张程, 李红艺, 等.恩替卡韦长期抗病毒治疗慢性乙型肝炎对患者肾脏功能的影响[J].临床和实验医学杂志, 2017, 16 (15) :1502-1505.
|
DownLoad: